Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.
Dezza FC, Pulido LB, Borreguero IB, Pérez FD, Jiménez VP, de la Rosa Riestra S, Bravo-Ferrer JM, Palacios-Baena ZR, Zuñiga MÁL, Cobo F, Gómez-Junyent J, Horcajada JP, Merino E, Parra M, López-Contreras J, Rivera A, Regueiro DS, Garcia MP, Cardenas SL, Sánchez MCG, Camacho IP, Ramos SMM, Jiménez EL, García AIA, Pérez-Rodríguez MT, Sousa A, Ruiz MS, de Las Revillas Almajano FA, Pérez LG, Agirre JG, Cano Á, Martínez-Marcos FJ, País MJG, Sánchez RE, de la Villa S, Ara JRY, Esteban-Moreno MÁ, Ruiz-Sancho A, Aragón MP, Fernández JA, Blandino AMB, Vilchez-Rueda HH, Álvarez-Marín R, Palacios AR, Vázquez EG, Álvarez EN, Rosso-Fernández C, Gutiérrez-Gutiérrez B, Pascual Á, López-Cerero L, Rodríguez-Baño J; ASTARTÉ-GEIRAS study group.
Dezza FC, et al. Among authors: aragon mp.
Lancet. 2026 Aug 1;408(10553):430-439. doi: 10.1016/S0140-6736(26)00760-9. Epub 2026 Jul 9.
Lancet. 2026.
PMID: 42425122
Clinical Trial.